VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back

Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?

chart

Four venture capital firms have raised more than $1bn in new money for life science and health care investments, which could be divided among a large number of biotechnology companies if a recent trend toward smaller funding rounds continues for US and EU firms.

There's been some concern during the past few record-breaking years of biotech venture capital financing about the decline in seed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip